Association of Neurodevelopmental Outcomes and Neonatal Morbidities of Extremely Premature Infants With Differential Exposure to Antenatal Steroids
- PMID: 27723868
- PMCID: PMC5294968
- DOI: 10.1001/jamapediatrics.2016.1936
Association of Neurodevelopmental Outcomes and Neonatal Morbidities of Extremely Premature Infants With Differential Exposure to Antenatal Steroids
Abstract
Importance: Many premature infants are born without exposure to antenatal steroids (ANS) or with incomplete courses. This study evaluates the dose-dependent effect of ANS on rates of neonatal morbidities and early childhood neurodevelopmental outcomes of extremely premature infants.
Objective: To compare rates of neonatal morbidities and 18- to 22-month neurodevelopmental outcomes of extremely premature infants exposed to no ANS or partial or complete courses of ANS.
Design, setting, and participants: In this observational cohort study, participants were extremely premature infants (birth weight range, 401-1000 g; gestational age, 22-27 weeks) who were born at participating centers of the National Institute of Child Health and Human Development Neonatal Research Network between January 2006 and December 2011. Data were analyzed between October 2013 and May 2016.
Main outcomes and measures: Rates of death or neurodevelopmental impairment at 18 to 22 months' corrected age. Neurodevelopmental impairment was defined as the presence of any of the following: moderate to severe cerebral palsy, a cognitive score less than 85 on the Bayley Scales of Infant and Toddler Development III, blindness, or deafness.
Results: There were 848 infants in the no ANS group, 1581 in the partial ANS group, and 3692 in the complete ANS group; the mean (SD) birth weights were 725 (169), 760 (173), and 753 (170) g, respectively, and the mean (SD) gestational ages were 24.5 (1.4), 24.9 (2), and 25.1 (1.1) weeks. Of 6121 eligible infants, 4284 (70.0%) survived to 18- to 22-month follow-up, and data were available for 3892 of 4284 infants (90.8%). Among the no, partial, and complete ANS groups, there were significant differences in the rates of mortality (43.1%, 29.6%, and 25.2%, respectively), severe intracranial hemorrhage among survivors (23.3%, 19.1%, and 11.7%), death or necrotizing enterocolitis (48.1%, 37.1%, and 32.5%), and death or bronchopulmonary dysplasia (74.9%, 68.9%, and 65.5%). Additionally, death or neurodevelopmental impairment occurred in 68.1%, 54.4%, and 48.1% of patients in the no, partial, and complete ANS groups, respectively. Logistic regression analysis revealed that complete (odds ratio, 0.63; 95% CI, 0.53-0.76) and partial (odds ratio, 0.77; 95% CI, 0.63-0.95) ANS courses were associated with lower rates of death or neurodevelopmental impairment compared with the no ANS group. The reduction in the rate of death or neurodevelopmental impairment associated with exposure to a complete ANS course may be mediated through a reduction in rates of severe intracranial hemorrhage and/or cystic periventricular leukomalacia in the neonatal period.
Conclusions and relevance: Antenatal steroid exposure was associated with a dose-dependent protective effect against death or neurodevelopmental impairment in extremely preterm infants. The effect was partly mediated by ANS-associated reductions in rates of severe intracranial hemorrhage and/or cystic periventricular leukomalacia. These results support prompt administration of ANS, with the goal of a complete course prior to delivery.
Conflict of interest statement
Disclosures: None reported.
Figures
Similar articles
-
Association of Antenatal Corticosteroids With Mortality, Morbidity, and Neurodevelopmental Outcomes in Extremely Preterm Multiple Gestation Infants.JAMA Pediatr. 2016 Jun 1;170(6):593-601. doi: 10.1001/jamapediatrics.2016.0104. JAMA Pediatr. 2016. PMID: 27088897 Free PMC article.
-
Neurodevelopmental outcome of extremely premature infants exposed to incomplete, no or complete antenatal steroids.J Matern Fetal Neonatal Med. 2013 Oct;26(15):1542-7. doi: 10.3109/14767058.2013.791273. Epub 2013 May 7. J Matern Fetal Neonatal Med. 2013. PMID: 23565886
-
Neurodevelopmental and Behavioral Outcomes in Extremely Premature Neonates With Ventriculomegaly in the Absence of Periventricular-Intraventricular Hemorrhage.JAMA Pediatr. 2018 Jan 1;172(1):32-42. doi: 10.1001/jamapediatrics.2017.3545. JAMA Pediatr. 2018. PMID: 29181530 Free PMC article.
-
Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.Neonatology. 2015;107(4):358-9. doi: 10.1159/000381132. Epub 2015 Jun 5. Neonatology. 2015. PMID: 26044104 Review.
-
Outcomes of infants born at 22 and 23 weeks' gestation.Pediatrics. 2013 Jul;132(1):62-71. doi: 10.1542/peds.2012-2857. Epub 2013 Jun 3. Pediatrics. 2013. PMID: 23733804 Review.
Cited by
-
Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms.Neural Regen Res. 2024 Jul 1;19(7):1499-1508. doi: 10.4103/1673-5374.385855. Epub 2023 Sep 22. Neural Regen Res. 2024. PMID: 38051892 Free PMC article.
-
Role of Postnatal Corticosteroids in the Treatment or Prevention of Bronchopulmonary Dysplasia.Sisli Etfal Hastan Tip Bul. 2023 Jun 20;57(2):171-181. doi: 10.14744/SEMB.2023.80688. eCollection 2023. Sisli Etfal Hastan Tip Bul. 2023. PMID: 37899802 Free PMC article. Review.
-
Antenatal Corticosteroids at 21-23 Weeks of Gestation.Obstet Gynecol. 2024 Jan 1;143(1):35-43. doi: 10.1097/AOG.0000000000005352. Epub 2023 Sep 13. Obstet Gynecol. 2024. PMID: 37708497
-
Antenatal Steroids, Prophylactic Indomethacin, and the Risk of Spontaneous Intestinal Perforation.J Pediatr. 2023 Aug;259:113457. doi: 10.1016/j.jpeds.2023.113457. Epub 2023 May 11. J Pediatr. 2023. PMID: 37172814
-
Multiprofessional cross-site working between a level 1 and a level 3 neonatal unit: a retrospective cohort study.BMJ Paediatr Open. 2022 Sep;6(1):e001581. doi: 10.1136/bmjpo-2022-001581. BMJ Paediatr Open. 2022. PMID: 36645761 Free PMC article.
References
-
- Crowley R, Chalmers I, Keirse MJ. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol. 1990;97(1):11–25. - PubMed
-
- Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515–525. - PubMed
-
- Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3(3):CD004454. - PubMed
-
- Chawla S, Natarajan G, Rane S, Thomas R, Cortez J, Lua J. Outcomes of extremely low birth weight infants with varying doses and intervals of antenatal steroid exposure. J Perinat Med. 2010;38(4):419–423. - PubMed
-
- Doyle LW, Kitchen WH, Ford GW, Rickards AL, Kelly EA. Antenatal steroid therapy and 5-year outcome of extremely low birth weight infants. Obstet Gynecol. 1989;73(5, pt 1):743–746. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical